{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T04:37:38Z","timestamp":1791607058820,"version":"4.3.4"},"reference-count":40,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2014,1,28]],"date-time":"2014-01-28T00:00:00Z","timestamp":1390867200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2014,3]]},"abstract":"<jats:title>Summary<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The alginate\u2013antacid, Gaviscon Double Action (Gaviscon DA; Reckitt Benckiser, Slough, UK) suppresses reflux after meals by creating a gel\u2010like barrier that caps and displaces the acid pocket distal to the oesophago\u2010gastric junction. The effect of Gaviscon DA on reflux and dyspepsia symptoms has not yet been demonstrated with a modern trial design.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>A pilot study to assess the efficacy and safety of Gaviscon DA compared with matched placebo for decreasing upper gastrointestinal symptoms in symptomatic gastro\u2010oesophageal reflux disease (<jats:styled-content style=\"fixed-case\">GERD<\/jats:styled-content>) patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A randomised, double\u2010blind, parallel group study was performed in 110 patients with symptoms of <jats:styled-content style=\"fixed-case\">GERD<\/jats:styled-content>. Patients received Gaviscon <jats:styled-content style=\"fixed-case\">DA<\/jats:styled-content> or placebo tablets for 7 consecutive days. The primary endpoint compared the change in overall Reflux Disease Questionnaire (<jats:styled-content style=\"fixed-case\">RDQ<\/jats:styled-content><jats:italic>)<\/jats:italic> symptom score (combined heartburn\/regurgitation\/dyspepsia). Secondary endpoints assessed individual dimensions, <jats:styled-content style=\"fixed-case\">GERD<\/jats:styled-content> dimension (heartburn and regurgitation) and overall treatment evaluation (<jats:styled-content style=\"fixed-case\">OTE<\/jats:styled-content>).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>There was a greater decrease in overall <jats:styled-content style=\"fixed-case\">RDQ<\/jats:styled-content> symptom score in the Gaviscon <jats:styled-content style=\"fixed-case\">DA<\/jats:styled-content> group compared with the placebo group (Least Squares Mean difference \u22120.55; <jats:italic>P<\/jats:italic>\u00a0=\u00a00.0033), and for each of the dimensions independently. Patients in the Gaviscon <jats:styled-content style=\"fixed-case\">DA<\/jats:styled-content> group evaluated their overall treatment response higher than patients in the placebo group [mean (standard deviation) <jats:styled-content style=\"fixed-case\">OTE<\/jats:styled-content> 4.1 (2.44) vs. 1.9 (3.34); <jats:italic>P<\/jats:italic>\u00a0=\u00a00.0005]. No differences in the incidence of adverse events were observed between treatment groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Gaviscon <jats:styled-content style=\"fixed-case\">DA<\/jats:styled-content> decreases reflux and dyspeptic symptoms in <jats:styled-content style=\"fixed-case\">GERD<\/jats:styled-content> patients compared with matched placebo and has a favourable benefit\u2010risk balance. Larger scale clinical investigations of medications targeting the acid pocket are warranted. (EudraCT, 2012\u2010002188\u201084)<\/jats:p><\/jats:sec>","DOI":"10.1111\/apt.12640","type":"journal-article","created":{"date-parts":[[2014,1,29]],"date-time":"2014-01-29T01:18:57Z","timestamp":1390958337000},"page":"595-602","source":"Crossref","is-referenced-by-count":64,"title":["Randomised clinical trial: relief of upper gastrointestinal symptoms by an acid pocket\u2010targeting alginate\u2013antacid (Gaviscon Double Action) \u2013 a double\u2010blind, placebo\u2010controlled, pilot study in gastro\u2010oesophageal reflux disease"],"prefix":"10.1111","volume":"39","author":[{"given":"E.","family":"Thomas","sequence":"first","affiliation":[{"name":"Category Development Organisation Reckitt Benckiser Slough UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Wade","sequence":"additional","affiliation":[{"name":"CPS Research Glasgow UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Crawford","sequence":"additional","affiliation":[{"name":"CPS Research Glasgow UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Jenner","sequence":"additional","affiliation":[{"name":"Global CMV Reckitt Benckiser Slough UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Levinson","sequence":"additional","affiliation":[{"name":"Global CMV Reckitt Benckiser Slough UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Wilkinson","sequence":"additional","affiliation":[{"name":"Global CMV Reckitt Benckiser Slough UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,1,28]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2004.051821"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.3122\/jabfm.18.5.393"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2005.00343.x"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2008.03671.x"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-009-1004-0"},{"key":"e_1_2_7_7_1","first-page":"2128","article-title":"The burden of gastrointestinal and liver diseases, 2006","volume":"101","author":"Shaheen NJ","year":"2006","journal-title":"J Gastroenterol"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-7-90"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2006.00630.x"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-2050.2007.00650.x"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0399-8320(05)80756-0"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1159\/000121354"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2004.053355"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2982.2011.01845.x"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2001.27997"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2013.132"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2008.161927"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2006.109421"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2009.178061"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2007.01488.x"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2013.06.008"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2013.04.046"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2005.01.036"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.3109\/03639040903388290"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2000.00759.x"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12318"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2004.02298.x"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2005.074690"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2011.04678.x"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2011-300926"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(12)60353-9"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2001.03451.x"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(94)90036-1"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(89)90005-6"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007999909114086"},{"key":"e_1_2_7_36_1","unstructured":"The Scottish Government.Statistics. Health of Scotland's population \u2013 Healthy weight. Available at:http:\/\/www.scotland.gov.uk\/Topics\/Statistics\/Browse\/Health\/TrendObesity. Accessed December 5 2013."},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2008.09.007"},{"key":"e_1_2_7_38_1","unstructured":"Reckitt Benckiser.Gaviscon Double Action Summary of Product Characteristics. Last revised 28\/01\/2011."},{"key":"e_1_2_7_39_1","unstructured":"U.S. Department of Health and Human Services. Food and Drug Administration.Guidance for the Industry: Patient\u2010reported outcome measures: use in medical product development to support labeling claims.2009."},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.5056\/jnm.2011.17.4.381"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2009.200063"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fapt.12640","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/apt.12640","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T17:48:33Z","timestamp":1696528113000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/apt.12640"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,28]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["10.1111\/apt.12640"],"URL":"https:\/\/doi.org\/10.1111\/apt.12640","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,28]]}}}